EGFR and non-small cell lung carcinoma: Significant progress in this field was demonstrated by the FLAURA2 trial in 2023, which confirmed the efficacy of osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), in combination with chemotherapy, achieving a progression-free survival (PFS) of 25.5 months in patients with advanced EGFR-mutant NSCLC [4].